Frontiers in Immunology (Jul 2021)
Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine
- Jules Russick,
- Pierre-Emmanuel Foy,
- Nathalie Josseaume,
- Maxime Meylan,
- Nadine Ben Hamouda,
- Nadine Ben Hamouda,
- Nadine Ben Hamouda,
- Amos Kirilovsky,
- Amos Kirilovsky,
- Amos Kirilovsky,
- Carine El Sissy,
- Carine El Sissy,
- Carine El Sissy,
- Eric Tartour,
- David M. Smadja,
- David M. Smadja,
- Alexandre Karras,
- Alexandre Karras,
- Jean-Sébastien Hulot,
- Jean-Sébastien Hulot,
- Marine Livrozet,
- Marine Livrozet,
- Antoine Fayol,
- Antoine Fayol,
- Jean-Benoit Arlet,
- Jean-Benoit Arlet,
- Jean-Luc Diehl,
- Jean-Luc Diehl,
- Marie-Agnès Dragon-Durey,
- Marie-Agnès Dragon-Durey,
- Marie-Agnès Dragon-Durey,
- Marie-Agnès Dragon-Durey,
- Franck Pagès,
- Franck Pagès,
- Franck Pagès,
- Isabelle Cremer
Affiliations
- Jules Russick
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- Pierre-Emmanuel Foy
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- Nathalie Josseaume
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- Maxime Meylan
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- Nadine Ben Hamouda
- Hopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France
- Nadine Ben Hamouda
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Integrative Cancer Immunology F-75006, Paris, France
- Nadine Ben Hamouda
- Sorbonne Universite, Paris, France
- Amos Kirilovsky
- Hopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France
- Amos Kirilovsky
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Integrative Cancer Immunology F-75006, Paris, France
- Amos Kirilovsky
- Sorbonne Universite, Paris, France
- Carine El Sissy
- Hopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France
- Carine El Sissy
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Integrative Cancer Immunology F-75006, Paris, France
- Carine El Sissy
- Sorbonne Universite, Paris, France
- Eric Tartour
- Department of Immunology, Hôpital Europeen Georges Pompidou, AP-HP, Paris, France
- David M. Smadja
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), Paris, France
- David M. Smadja
- F-CRIN INNOVTE, Saint-Étienne, France
- Alexandre Karras
- Department of Nephrology, Hopital Europeen Georges Pompidou, AP-HP, Paris, France
- Alexandre Karras
- Department of Nephrology, Universite de Paris, Paris, France
- Jean-Sébastien Hulot
- 0Université de Paris, INSERM, PARCC, Paris, France
- Jean-Sébastien Hulot
- 1CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France
- Marine Livrozet
- 0Université de Paris, INSERM, PARCC, Paris, France
- Marine Livrozet
- 1CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France
- Antoine Fayol
- 0Université de Paris, INSERM, PARCC, Paris, France
- Antoine Fayol
- 1CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France
- Jean-Benoit Arlet
- Department of Nephrology, Universite de Paris, Paris, France
- Jean-Benoit Arlet
- 2Department of Internal Medicine, Hopital Europeen Georges Pompidou, AP-HP, Paris, France
- Jean-Luc Diehl
- 3Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Jean-Luc Diehl
- 4Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Paris, France
- Marie-Agnès Dragon-Durey
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- Marie-Agnès Dragon-Durey
- Hopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France
- Marie-Agnès Dragon-Durey
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Integrative Cancer Immunology F-75006, Paris, France
- Marie-Agnès Dragon-Durey
- Sorbonne Universite, Paris, France
- Franck Pagès
- Hopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France
- Franck Pagès
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Integrative Cancer Immunology F-75006, Paris, France
- Franck Pagès
- Sorbonne Universite, Paris, France
- Isabelle Cremer
- Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France
- DOI
- https://doi.org/10.3389/fimmu.2021.701273
- Journal volume & issue
-
Vol. 12
Abstract
SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using in silico analysis on drug signature database, we identify differential therapeutics that specifically correspond to each group of patients. From this signature, we propose a score—the SARS-Score—composed of easily quantifiable biomarkers, to classify hospitalized patients upon arrival to adapt treatment according to their immune profile.
Keywords
- COVID-19
- immunologic profile
- personalized medicine/personalized health care
- score
- therapeutic strategy
